<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02140216</url>
  </required_header>
  <id_info>
    <org_study_id>Si 081/2557 (EC3)</org_study_id>
    <nct_id>NCT02140216</nct_id>
  </id_info>
  <brief_title>Immunomodulation Effect of Blood Transfusion</brief_title>
  <official_title>Allogeneic Red Cell Transfusion and Its Influence on Relevant Humoral and Cellular Immunological Parameters</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mahidol University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Wolf Schleinzer Stiftung zur Wissenschafts- und Bildungsf√∂rderung, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mahidol University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      An increasing number of publications have demonstrated that homologous (allogeneic) blood&#xD;
      transfusion impairs outcome in cancer and non-cancer patients. Leukocyte depletion of blood&#xD;
      products cannot solve these problems, despite improved quality of red cells; a recent study&#xD;
      demonstrated deteriorated outcome of cancer patients with elective colon surgery and&#xD;
      transfusion of leukocyte depleted allogeneic blood.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All patients undergo the identical anesthesiological procedure, including premedication,&#xD;
      general anesthesia with endotracheal intubation, monitoring and postoperative pain therapy&#xD;
      and mobilization.Surgery is performed by the identical team performing a standardized&#xD;
      technique.&#xD;
&#xD;
      Transfusion regimen The 'trigger' for homologous red cell transfusion intra- and&#xD;
      postoperatively is the actual hematocrit concentration. Transfusion depends on discretion of&#xD;
      the treating physicians. Number of units transfused, amount of blood loss, time, reasoning&#xD;
      and decision maker are recorded.&#xD;
&#xD;
      Blood samples Within the kind of surgical procedures chosen for this study the chance of red&#xD;
      cell transfusion is about 60 - 70%. In terms of figures 10 non-transfused cases could be&#xD;
      gained within 40 cases in total. However, transfusion or non-transfusion does not happen in a&#xD;
      row. We expect the total number of patients with blood withdrawal to be between 50 and 60.&#xD;
      Additionally withdrawn samples currently not used for analysis will stored for further&#xD;
      studies.&#xD;
&#xD;
      The purpose to include non-transfused otherwise fully comparable patients is to distinguish&#xD;
      between trauma (operation) and transfusion and their influence on immune modulation. Within&#xD;
      the studies about blood transfusion and immune modulation only some few made this&#xD;
      differentiation. In patients with colorectal cancer surgery randomized groups with autologous&#xD;
      predonation and patients with allogeneic transfusion only have been compared. However, within&#xD;
      the latter (allogeneic) group of 27 patients only 13 had to be transfused, thus creating a&#xD;
      non-transfusion group of 14 patients. These 14 non-transfused patients remained within the&#xD;
      study being compared with autologous and allogeneic transfused patients. Operative trauma and&#xD;
      allogeneic transfusion both increased the secretion of several cytokines including tumor&#xD;
      necrosis factor (TNF) alpha and Interleukin-10; this effect was less pronounced in patients&#xD;
      with autologous- and without any transfusion. Another group studied forty three orthopedic&#xD;
      patients with total knee- or hip-arthroplasty, initially to compare autologous to allogeneic&#xD;
      red cell transfusion. They had to change their protocol due to the small number of allogeneic&#xD;
      transfusions (8 of 43). Including perioperatively transfused patients only (n = 37) they&#xD;
      found an increase in immune regulatory cytokine Interleukin (IL)-10 after red cell&#xD;
      transfusion, which was most pronounced 7 days after surgery, whereas there was only a mild&#xD;
      increase in non- or autologous transfused patients. Unfortunately they did not differentiate&#xD;
      between autologous-and non-transfused patients. Thus their data could not reveal the effect&#xD;
      of surgery itself on the analyzed parameters.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 2014</start_date>
  <completion_date type="Actual">April 10, 2018</completion_date>
  <primary_completion_date type="Actual">June 18, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Macrophage inflammatory protein 1 alpha (MIP-1a)</measure>
    <time_frame>5 days</time_frame>
    <description>Blood sample on preoperative, postoperative day 1, 3, 5</description>
  </primary_outcome>
  <primary_outcome>
    <measure>macrophage inflammatoryprotein 1 beta (MIP-1b)</measure>
    <time_frame>5 days</time_frame>
    <description>Blood sample on preoperative, postoperative day 1, 3, 5</description>
  </primary_outcome>
  <primary_outcome>
    <measure>platelet-derived growth factor-BB</measure>
    <time_frame>5 days</time_frame>
    <description>Blood sample on preoperative, postoperative day 1, 3, 5</description>
  </primary_outcome>
  <primary_outcome>
    <measure>RANTES</measure>
    <time_frame>5 days</time_frame>
    <description>Blood sample on preoperative, postoperative day 1, 3, 5</description>
  </primary_outcome>
  <primary_outcome>
    <measure>tumour TNF alpha</measure>
    <time_frame>5 days</time_frame>
    <description>Blood sample on preoperative, postoperative day 1, 3, 5</description>
  </primary_outcome>
  <primary_outcome>
    <measure>VEGF</measure>
    <time_frame>5 days</time_frame>
    <description>Blood sample on preoperative, postoperative day 1, 3, 5</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ferritin</measure>
    <time_frame>5 days</time_frame>
    <description>Blood sample on preoperative, postoperative day 1, 3, 5</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fibrinogen</measure>
    <time_frame>5 days</time_frame>
    <description>Blood sample on preoperative, postoperative day 1, 3, 5</description>
  </primary_outcome>
  <primary_outcome>
    <measure>procalcitonin</measure>
    <time_frame>5 days</time_frame>
    <description>Blood sample on preoperative, postoperative day 1, 3, 5</description>
  </primary_outcome>
  <primary_outcome>
    <measure>interleukin</measure>
    <time_frame>5 days</time_frame>
    <description>Blood sample on preoperative, postoperative day 1, 3, 5</description>
  </primary_outcome>
  <primary_outcome>
    <measure>basic fibroblast growth factor (B-FGF)</measure>
    <time_frame>5 days</time_frame>
    <description>Blood sample on preoperative, postoperative day 1, 3, 5</description>
  </primary_outcome>
  <primary_outcome>
    <measure>eotaxin (monocyte chemotactic proteins)</measure>
    <time_frame>5 days</time_frame>
    <description>Blood sample on preoperative, postoperative day 1, 3, 5</description>
  </primary_outcome>
  <primary_outcome>
    <measure>G-CSF</measure>
    <time_frame>5 days</time_frame>
    <description>Blood sample on preoperative, postoperative day 1, 3, 5</description>
  </primary_outcome>
  <primary_outcome>
    <measure>GM-CSF</measure>
    <time_frame>5 days</time_frame>
    <description>Blood sample on preoperative, postoperative day 1, 3, 5</description>
  </primary_outcome>
  <primary_outcome>
    <measure>IFN-alpha</measure>
    <time_frame>5 days</time_frame>
    <description>Blood sample on preoperative, postoperative day 1, 3, 5</description>
  </primary_outcome>
  <primary_outcome>
    <measure>IP-10</measure>
    <time_frame>5 days</time_frame>
    <description>Blood sample on preoperative, postoperative day 1, 3, 5</description>
  </primary_outcome>
  <primary_outcome>
    <measure>MCP-1</measure>
    <time_frame>5 days</time_frame>
    <description>Blood sample on preoperative, postoperative day 1, 3, 5</description>
  </primary_outcome>
  <primary_outcome>
    <measure>MCAF</measure>
    <time_frame>5 days</time_frame>
    <description>Blood sample on preoperative, postoperative day 1, 3, 5</description>
  </primary_outcome>
  <primary_outcome>
    <measure>serum amyloid A</measure>
    <time_frame>5 days</time_frame>
    <description>Blood sample on preoperative, postoperative day 1, 3, 5</description>
  </primary_outcome>
  <primary_outcome>
    <measure>tissue plasminogen activator</measure>
    <time_frame>5 days</time_frame>
    <description>Blood sample on preoperative, postoperative day 1, 3, 5</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Postoperative non-surgical complications</measure>
    <time_frame>30 days</time_frame>
    <description>Infection, thrombosis, pulmonary affection</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CD2 Cellular immunologic parameter (non-radioisotope),</measure>
    <time_frame>5 days</time_frame>
    <description>Blood sample on preoperative, postoperative day 1, 3, 5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD3 Cellular immunologic parameter (non-radioisotope),</measure>
    <time_frame>5 days</time_frame>
    <description>Blood sample on preoperative, postoperative day 1, 3, 5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD4 Cellular immunologic parameter (non-radioisotope),</measure>
    <time_frame>5 days</time_frame>
    <description>Blood sample on preoperative, postoperative day 1, 3, 5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD 8 Cellular immunologic parameter (non-radioisotope),</measure>
    <time_frame>5 days</time_frame>
    <description>preoperative, postoperative day 1, 3, 5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD 8 Cellular immunologic parameter (non-radioisotope),</measure>
    <time_frame>5 days</time_frame>
    <description>Blood sample on preoperative, postoperative day 1, 3, 5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD 25 Cellular immunologic parameter (non-radioisotope),</measure>
    <time_frame>5 days</time_frame>
    <description>Blood sample on preoperative, postoperative day 1, 3, 5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD 30 Cellular immunologic parameter (non-radioisotope),</measure>
    <time_frame>5 days</time_frame>
    <description>Blood sample on preoperative, postoperative day 1, 3, 5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD 19 Cellular immunologic parameter (non-radioisotope),</measure>
    <time_frame>5 days</time_frame>
    <description>Blood sample on preoperative, postoperative day 1, 3, 5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD 20 Cellular immunologic parameter (non-radioisotope),</measure>
    <time_frame>5 days</time_frame>
    <description>Blood sample on preoperative, postoperative day 1, 3, 5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD 138 Cellular immunologic parameter (non-radioisotope),</measure>
    <time_frame>5 days</time_frame>
    <description>Blood sample on preoperative, postoperative day 1, 3, 5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD 56 Cellular immunologic parameter (non-radioisotope),</measure>
    <time_frame>5 days</time_frame>
    <description>Blood sample on preoperative, postoperative day 1, 3, 5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD 303 Cellular immunologic parameter (non-radioisotope),</measure>
    <time_frame>5 days</time_frame>
    <description>Blood sample on preoperative, postoperative day 1, 3, 5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CLT cytotoxicity (non-radioisotope),</measure>
    <time_frame>5 days</time_frame>
    <description>Blood sample on preoperative, postoperative day 1, 3, 5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD 304</measure>
    <time_frame>5 days</time_frame>
    <description>Blood sample on preoperative, postoperative day 1, 3, 5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NK cytotoxicity</measure>
    <time_frame>5 days</time_frame>
    <description>Blood sample on preoperative, postoperative day 1, 3, 5</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">60</enrollment>
  <condition>Incompatible Blood Transfusion</condition>
  <condition>Immune Defect</condition>
  <condition>Surgery</condition>
  <arm_group>
    <arm_group_label>Day 0 blood transfusion</arm_group_label>
    <description>Patients undergoing elective spine surgery receiving intra- or immediate-postoperative red cell blood transfusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Day 1 or 2 blood transfusion</arm_group_label>
    <description>Patients undergoing elective spine surgery receiving first red cell blood transfusion on day 1 or 2 after surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No blood transfusion</arm_group_label>
    <description>Patients undergoing elective spine surgery receiving no blood transfusion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>No blood transfusion</intervention_name>
    <description>No blood transfusion</description>
    <arm_group_label>No blood transfusion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Day 0 blood transfusion</intervention_name>
    <description>Patients undergoing elective spine surgery receiving intra- or immediate-postoperative red cell blood transfusion.</description>
    <arm_group_label>Day 0 blood transfusion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Day 1 or 2 blood transfusion</intervention_name>
    <description>Patients undergoing elective spine surgery receiving first red cell blood transfusion on day 1 or 2 after surgery.</description>
    <arm_group_label>Day 1 or 2 blood transfusion</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients undergoing elective spine surgery/&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients undergoing elective spine surgery&#xD;
&#xD;
          -  American Society of Anesthesiologist Risk score classification (ASA) I-III&#xD;
&#xD;
          -  Hemoglobin &gt; 9 gm/dL&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who have the concomitant condition; cancer, history of heart disease&#xD;
             including, heart failure, coronary artery disease, hypertension treated with more than&#xD;
             one medicament, serum creatinine &gt; 1.5 mg/dL., stroke, neurologic and mental deficits,&#xD;
             epilepsy, general or local infection (site of surgery), coagulation disorders,&#xD;
             rheumatoid arthritis.&#xD;
&#xD;
          -  Patients who have one of the following drugs; aspirin, methotrexate, cyclosporin,&#xD;
             qualaquin&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sirilak Suksompong, MD</last_name>
    <role>Study Director</role>
    <affiliation>Mahidol University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Faculty of Medicine Siriraj Hospital, Mahidol University</name>
      <address>
        <city>Bangkok</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <reference>
    <citation>Marik PE, Corwin HL. Efficacy of red blood cell transfusion in the critically ill: a systematic review of the literature. Crit Care Med. 2008 Sep;36(9):2667-74. doi: 10.1097/CCM.0b013e3181844677. Review. Erratum in: Crit Care Med. 2008 Nov;36(11):3134.</citation>
    <PMID>18679112</PMID>
  </reference>
  <reference>
    <citation>von Bormann B, Wirtz S, Weiler J, von Bormann C, Trobisch H. [Quality of whole blood as a result of storage and preparation (inline-leukocyte depletion). Evidence for autologous predeposit]. Anasthesiol Intensivmed Notfallmed Schmerzther. 2000 May;35(5):326-32. German.</citation>
    <PMID>10858843</PMID>
  </reference>
  <reference>
    <citation>Ghio M, Contini P, Negrini S, Mazzei C, Zocchi MR, Poggi A. Down regulation of human natural killer cell-mediated cytolysis induced by blood transfusion: role of transforming growth factor-Œ≤(1), soluble Fas ligand, and soluble Class I human leukocyte antigen. Transfusion. 2011 Jul;51(7):1567-73. doi: 10.1111/j.1537-2995.2010.03000.x. Epub 2011 Jan 7.</citation>
    <PMID>21214580</PMID>
  </reference>
  <reference>
    <citation>Leal-Noval SR, Mu√±oz-G√≥mez M, Arellano V, Adsuar A, Jim√©nez-S√°nchez M, Corcia Y, Leal M. Influence of red blood cell transfusion on CD4+ T-helper cells immune response in patients undergoing cardiac surgery. J Surg Res. 2010 Nov;164(1):43-9. doi: 10.1016/j.jss.2009.03.010. Epub 2009 Apr 18.</citation>
    <PMID>19592026</PMID>
  </reference>
  <reference>
    <citation>Heiss MM, Fasol-Merten K, Allgayer H, Str√∂hlein MA, Tarabichi A, Wallner S, Eissner HI, Jauch KW, Schildberg FW. Influence of autologous blood transfusion on natural killer and lymphokine-activated killer cell activities in cancer surgery. Vox Sang. 1997;73(4):237-45.</citation>
    <PMID>9407641</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>May 5, 2014</study_first_submitted>
  <study_first_submitted_qc>May 12, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 16, 2014</study_first_posted>
  <last_update_submitted>August 31, 2021</last_update_submitted>
  <last_update_submitted_qc>August 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mahidol University</investigator_affiliation>
    <investigator_full_name>Benno von Bormann</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Blood transfusion</keyword>
  <keyword>Immune</keyword>
  <keyword>Surgery</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

